Author

Eleonora A. M. Festen

PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
PROTEOMIC ANALYSES DO NOT REVEAL SUBCLINICAL INFLAMMATION IN FATIGUED PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE

Eleonora A. M. Festen  et al.

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Eleonora A. M. Festen  et al.

TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Eleonora A. M. Festen  et al.

DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE
DISTINCT MUCOSAL HOST-MICROBE INTERACTIONS IN RELATION TO CLINICAL PHENOTYPES IN INFLAMMATORY BOWEL DISEASE

Eleonora A. M. Festen  et al.

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

Eleonora A. M. Festen  et al.

SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE
SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE

Eleonora A. M. Festen  et al.

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Eleonora A. M. Festen  et al.

BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY
BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY

Eleonora A. M. Festen  et al.

DIETARY PATTERNS ARE REFLECTED IN THE PLASMA INFLAMMATORY PROTEOME OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
DIETARY PATTERNS ARE REFLECTED IN THE PLASMA INFLAMMATORY PROTEOME OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Eleonora A. M. Festen  et al.

IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING
IN-DEPTH CHARACTERIZATION OF THE SERUM ANTIBODY EPITOPE REPERTOIRE IN INFLAMMATORY BOWEL DISEASE BY HIGH-THROUGHPUT PHAGE-DISPLAYED IMMUNOPRECIPITATION SEQUENCING

Eleonora A. M. Festen  et al.

GUT MICROBIOME COMPOSITION AND FUNCTION ARE LINKED TO THE DEVELOPMENT OF (PRE)CANCEROUS COLONIC LESIONS IN A PROSPECTIVE FOLLOW UP STUDY OF THE DUTCH MICROBIOME PROJECT
GUT MICROBIOME COMPOSITION AND FUNCTION ARE LINKED TO THE DEVELOPMENT OF (PRE)CANCEROUS COLONIC LESIONS IN A PROSPECTIVE FOLLOW UP STUDY OF THE DUTCH MICROBIOME PROJECT

Eleonora A. M. Festen  et al.

THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF PHENOTYPE AND GENOTYPE ON THE PLASMA PROTEOME IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Eleonora A. M. Festen  et al.

Item 1 - 12 / 12
1